BSEBeryl Drugs LtdLowNeutral
Announced Sat, 21 Mar · 17:21 IST

DISCLOSURE UNDER REGULATION 29(2) OF SEBI (SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVERS) REGULATIONS, 2011

Promoter Stake BuyCreeping Acquisition Near ThresholdOwnership Changes View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-1.9%1-day move
₹21.40
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.9-5.1-14.0-9.9-11.3-11.9+19.0+5.7-11.2+3.6
Up moveDown movePending
AI summary

Mr. Sudhir Sethi, a main promoter of Beryl Drugs Ltd, acquired 800 equity shares (0.02% of total capital) through market transactions on 20-03-2026. His holding in the company increased from 4,78,183 shares (9.42%) to 4,78,983 shares (9.44%). The disclosure is filed under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The total equity share capital of the company stands unchanged at 50,71,700 shares. Part-B of the disclosure also lists other promoters — Sanjay Sethi, Sangita Sethi, and Soniya Sethi — as persons acting in concert.

Likely market impact

This is a very small open-market purchase by a promoter and is unlikely to have any meaningful impact on the stock price. It signals modest promoter confidence but represents a routine, minor increase in promoter holding, still well below any major regulatory threshold.